Commercialization: Page 3
-
Stock via Getty Images
Q&A // First 90 DaysDr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career
With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.
By Taren Grom • Dec. 9, 2022 -
Sarah Silbiger via Getty Images
An FDA proposal could make OTC switches easier. Here’s what the industry has to say
How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.
By Karissa Waddick • Dec. 5, 2022 -
Courtesy of Teva Pharmaceutical
Executive changes at Teva, Eversana could spell commercial growth in the new year
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Nov. 23, 2022 -
iStock via Getty Images
4 pioneering social media campaigns in pharma this year
The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate.
By Karissa Waddick • Nov. 17, 2022 -
Retrieved from Google image.
While DCTs get all the hype, some industry insiders say the future is a digital hybrid
Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.
By Michael Gibney • Nov. 1, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann
The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.
By Taren Grom • Oct. 26, 2022 -
Permission granted by Doug Langa
Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots
The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.
By Meagan Parrish • Oct. 25, 2022 -
Jackfoto via Getty Images
Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning
In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.
By Michael Gibney • Oct. 24, 2022 -
Alex Wong via Getty Images
Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps
Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.
By Karissa Waddick • Oct. 18, 2022 -
skynesher via Getty Images
Q&A // Biotech SpotlightCitius Pharmaceuticals sees golden opportunities in late-stage specialty assets
CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.
By Karissa Waddick • Oct. 11, 2022 -
Permission granted by Asia Kepka
Q&AHer antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
By Karissa Waddick • Oct. 6, 2022 -
iStock via Getty Images
Making MovesC-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Stock via Getty Images
Q&ACompass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success
The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression.
By Meagan Parrish • Sept. 27, 2022 -
BillionPhotos.com
Sponsored by EVERSANA3 keys to value for unlocking the promise of cell therapies
There is no question about the incredible clinical impact cell therapies can have on the lives of patients. However, this impact is the result of innovation that does not equate to a simple, straightforward commercialization process.
Sept. 26, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Foresite Capital’s Cindy Mesaros
The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive.
By Taren Grom • Sept. 7, 2022 -
Gabriel Kuchta via Getty Images
Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes
The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.
By Karissa Waddick • Aug. 31, 2022 -
Permission granted by Alvotech.
Hurdles remain in biosims market — but Alvotech is undeterred
The biosimilar developer is advancing a pipeline with high growth potential, including a copycat of Humira.
By Kelly Bilodeau • Aug. 29, 2022 -
Permission granted by Brian Goff.
Q&A // First 90 DaysFirst 90 Days: Agios Pharmaceuticals’ Brian Goff
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
By Alexandra Pecci • Aug. 22, 2022 -
Drew Angerer via Getty Images
3 ways pharma can prep for Biden’s sweeping drug pricing policies
Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.
By Karissa Waddick • Aug. 18, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Takeda Oncology’s Teresa Bitetti
Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.
By Taren Grom • Aug. 17, 2022 -
Sarah Silbiger via Getty Images
The FDA is mulling an OTC approval for a birth control. Will politics factor in?
Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma's OTC birth control application.
By Karissa Waddick • Aug. 15, 2022 -
Win McNamee/Staff via Getty Images
Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
By Michael Gibney • Aug. 11, 2022 -
Stock via Getty Images
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022 -
Ivan Balvan via Getty Images
Making MovesEditas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
By Karissa Waddick • Aug. 3, 2022 -
Permission granted by Catherine Owen.
Q&AA glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
By Meagan Parrish • Aug. 1, 2022
Previous
